HER2 Support Group Forums - View Single Post - The uncertainty of HER2+, AIB1, and tamoxifen

10-20-2004, 06:51 AM

I did a Google search and came up with this:
Conclusion: High AIB1 levels in breast tumors, especially those with low Her2, predict a more indolent course in breast cancer patients not receiving adjuvant therapy. But in patients receiving TAM, high AIB1, especially those with high Her2 have strikingly worse DFS, perhaps due to increasing agonist effects of the drug. If validated, these markers together might identify patients for alternative treatments.

I think it means that Tamoxifen can act like an estrogen, in stead of an estrogen antagonist in some situations. Maybe that's why my oncologist wants to start me on Aromatase Inhibitors. They seem to work better in Her2 pos patients.

10-20-2004, 06:51 AM	#6
Jacqueline Guest Posts: n/a	I did a Google search and came up with this: Conclusion: High AIB1 levels in breast tumors, especially those with low Her2, predict a more indolent course in breast cancer patients not receiving adjuvant therapy. But in patients receiving TAM, high AIB1, especially those with high Her2 have strikingly worse DFS, perhaps due to increasing agonist effects of the drug. If validated, these markers together might identify patients for alternative treatments. I think it means that Tamoxifen can act like an estrogen, in stead of an estrogen antagonist in some situations. Maybe that's why my oncologist wants to start me on Aromatase Inhibitors. They seem to work better in Her2 pos patients.